Return on Investment Analysis for Home Trial Support

This document is a benchmark study that analyzes the return on investment (ROI) for Home Trial Support (HTS) services in the context of a typical Phase 2 Parkinson's disease trial. It presents data on patient enrollment, trial duration, and recruitment efficiency, detailing how varying levels of HTS adoption can accelerate trial timelines. The study outlines that with a 30% HTS budget adoption, trials can achieve a 2.16-month reduction in time to top-line data and an 18% decrease in total recruitment time. It also highlights the geographical reach and appointment flexibility that HTS provides, which can significantly enhance patient participation and retention. The document includes statistical data on patient visits, cost breakdowns, and references to published evidence supporting the effectiveness of decentralized trials in improving recruitment rates. Overall, the analysis demonstrates the potential financial and operational benefits of incorporating HTS into clinical trial designs.